PURPOSE: Intubation of hypoxemic patients is associated with life-threatening adverse events. High-flow therapy by nasal cannula (HFNC) for preoxygenation before intubation has never been assessed by randomized study. Our objective was to evaluate the efficiency of HFNC for preoxygenation, compared to high fraction-inspired oxygen facial mask (HFFM). METHODS: Multicenter, randomized, open-labelled, controlled PREOXYFLOW trial (NCT 01747109) in six French intensive care units. Acute hypoxemic adults requiring intubation were randomly allocated to HFNC or HFFM. Patients were eligible if PaO2/FiO2 ratio was below 300 mmHg, respiratory rate at least 30/min and if they required FiO2 50% or more to obtain at least 90% oxygen saturation. HFNC was maintained throughout the procedure, whereas HFFM was removed at the end of general anaesthesia induction. Primary outcome was the lowest saturation throughout intubation procedure. Secondary outcomes included adverse events related to intubation, duration of mechanical ventilation and death. RESULTS: A total of 124 patients were randomized. In the intent-to-treat analysis, including 119 patients (HFNC n = 62; HFFM n = 57), the median (interquartile range) lowest saturation was 91.5% (80-96) for HFNC and 89.5% (81-95) for the HFFM group (p = 0.44). There was no difference for difficult intubation (p = 0.18), intubation difficulty scale, ventilation-free days (p = 0.09), intubation-related adverse events including desaturation <80% or mortality (p = 0.46). CONCLUSIONS: Compared to HFFM, HFNC as a preoxygenation device did not reduce the lowest level of desaturation.
RCT Entities:
PURPOSE: Intubation of hypoxemic patients is associated with life-threatening adverse events. High-flow therapy by nasal cannula (HFNC) for preoxygenation before intubation has never been assessed by randomized study. Our objective was to evaluate the efficiency of HFNC for preoxygenation, compared to high fraction-inspired oxygen facial mask (HFFM). METHODS: Multicenter, randomized, open-labelled, controlled PREOXYFLOW trial (NCT 01747109) in six French intensive care units. Acute hypoxemic adults requiring intubation were randomly allocated to HFNC or HFFM. Patients were eligible if PaO2/FiO2 ratio was below 300 mmHg, respiratory rate at least 30/min and if they required FiO2 50% or more to obtain at least 90% oxygen saturation. HFNC was maintained throughout the procedure, whereas HFFM was removed at the end of general anaesthesia induction. Primary outcome was the lowest saturation throughout intubation procedure. Secondary outcomes included adverse events related to intubation, duration of mechanical ventilation and death. RESULTS: A total of 124 patients were randomized. In the intent-to-treat analysis, including 119 patients (HFNC n = 62; HFFM n = 57), the median (interquartile range) lowest saturation was 91.5% (80-96) for HFNC and 89.5% (81-95) for the HFFM group (p = 0.44). There was no difference for difficult intubation (p = 0.18), intubation difficulty scale, ventilation-free days (p = 0.09), intubation-related adverse events including desaturation <80% or mortality (p = 0.46). CONCLUSIONS: Compared to HFFM, HFNC as a preoxygenation device did not reduce the lowest level of desaturation.
Authors: David R Janz; Matthew W Semler; Robert J Lentz; Daniel T Matthews; Tufik R Assad; Brett C Norman; Raj D Keriwala; Benjamin A Ferrell; Michael J Noto; Ciara M Shaver; Bradley W Richmond; Jeannette Zinggeler Berg; Todd W Rice Journal: Crit Care Med Date: 2016-11 Impact factor: 7.598
Authors: Margaret M Parker; Gabrielle Nuthall; Calvin Brown; Katherine Biagas; Natalie Napolitano; Lee A Polikoff; Dennis Simon; Michael Miksa; Eleanor Gradidge; Jan Hau Lee; Ashwin S Krishna; David Tellez; Geoffrey L Bird; Kyle J Rehder; David A Turner; Michelle Adu-Darko; Sholeen T Nett; Ashley T Derbyshire; Keith Meyer; John Giuliano; Erin B Owen; Janice E Sullivan; Keiko Tarquinio; Pradip Kamat; Ronald C Sanders; Matthew Pinto; G Kris Bysani; Guillaume Emeriaud; Yuki Nagai; Melissa A McCarthy; Karen H Walson; Paula Vanderford; Anthony Lee; Jesse Bain; Peter Skippen; Ryan Breuer; Sarah Tallent; Vinay Nadkarni; Akira Nishisaki Journal: Pediatr Crit Care Med Date: 2017-04 Impact factor: 3.624
Authors: Samir Jaber; Giacomo Bellani; Lluis Blanch; Alexandre Demoule; Andrés Esteban; Luciano Gattinoni; Claude Guérin; Nicholas Hill; John G Laffey; Salvatore Maurizio Maggiore; Jordi Mancebo; Paul H Mayo; Jarrod M Mosier; Paolo Navalesi; Michael Quintel; Jean Louis Vincent; John J Marini Journal: Intensive Care Med Date: 2017-08-07 Impact factor: 17.440
Authors: Samir Jaber; Marion Monnin; Mehdi Girard; Matthieu Conseil; Moussa Cisse; Julie Carr; Martin Mahul; Jean Marc Delay; Fouad Belafia; Gérald Chanques; Nicolas Molinari; Audrey De Jong Journal: Intensive Care Med Date: 2016-10-11 Impact factor: 17.440